$FUNR Corporate Strategy and new CTO https://ww
Post# of 98978

https://www.otcmarkets.com/stock/FUNR/news/Co...?id=478340
La Jolla, California May 24, 2025 FUNR (the Company) (OTCPK:FUNR) is formulating and finalizing its corporate and share structure for overall strategy and impending filings. This is the first of three Press Releases with OTC Markets. The third and final Press Release is scheduled for July 1, 2025. This timing clearly synchronizes with the end of Q2 2025 and the start of Q3 2025. The Board of Directors of FUNR feels this to be an excellent and opportune jumping off point for the Company’s transition. As the Company’s timelines are fluid, updates to our processes for the transition will be available on the Company’s website starting Friday May 30, 2025. The new website professionally showcases and delivers what we all want to know and in a timely, succinct manner. This includes details permitted by legal Counsel for Company news, share structure and filings with OTC Markets, FINRA and SEC.
With regards to so said filings, FUNR wishes to point out the complexity and myriad details required with certain forms and procedures such as Super 8-K. YouTube has multiple videos which explain Super 8-K Filing Requirements, its burdensome process and also the rewarding results of a successful filing. Leave it to say that any filings must be done thoroughly, correctly and truthfully lest rejection is sought. The Company stresses that its actions are “by the book” and strictly adhere to accepted rules, regulations and laws under OTC Markets, FINRA and SEC. The Company furthermore points out that many aspects of processes are beyond its control such as chronology of document filing processes, requests for additional information and acceptance. This being said, FUNR keeps its shareholders and the public at large as up to date with its current situation as permits.
Lastly FUNR wishes to announce a new addition to its team. Welcome James Nguyen as our CTO and Science Officer. His education and proven accomplishments are remarkable to say the least especially considering his age. He currently attends UC Berkely where he studies computer science and biotechnology. He has numerous contributions to large-scale data automation, complex laboratory analyses and collaborative scientific publications. For lack of a better phrase James is a bonafide “whiz kid” in many respects. His strength is with commercial applications of foundational AI models. He has a specialty in nuero-oncology research and early cancer detection using biomarkers in a convenient and user friendly device. James recently submitted a research project on Ionic liquids for a nanoscience and biomaterial class for Academic Review. In layman’s terms he combines AI with BioScience.

